Back
Multiple myeloma: patient outcomes in real-world practice.
Journal article

Multiple myeloma: patient outcomes in real-world practice.

  • Yong K Department of Haematology, University College London, London, UK. kwee.yong@ucl.ac.uk.
  • Delforge M Department of Haematology, UZ Leuven, Leuven, Belgium.
  • Driessen C Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland.
  • Fink L Kantar Health, Montrouge, France.
  • Flinois A Kantar Health, Montrouge, France.
  • Gonzalez-McQuire S Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland.
  • Safaei R Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland.
  • Karlin L Centre Hospitalier Lyon-Sud, Lyon, France.
  • Mateos MV Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • Raab MS Department of Internal Medicine, Heidelberg University Hospital, Heidelberg, Germany.
  • Schoen P Value Access & Policy, Amgen (Europe) GmbH, Zug, Switzerland.
  • Cavo M 'Seràgnoli' Institute of Hematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy.
Show more…
  • 2016-07-14
Published in:
  • British journal of haematology. - 2016
depth of response
duration of therapy
multiple myeloma
patient chart review
real-world practice
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Comorbidity
Cross-Sectional Studies
Disease Management
Disease Progression
Europe
Female
Health Care Surveys
Humans
Male
Middle Aged
Multiple Myeloma
Outcome Assessment, Health Care
Phenotype
Physicians
Retrospective Studies
Treatment Outcome
English With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We investigated patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK. In total, 435 physicians retrospectively reviewed 4997 patient charts. Profiles of patients diagnosed with multiple myeloma during the last 12 months were similar across countries; bone pain was the most common presentation. Median duration of first-line therapy was 6 months, followed by a median treatment-free interval of 10 months; both these decreased with increasing lines of therapy, as did time to progression. Depth of response, as assessed by the treating physician, also decreased with each additional line of therapy: 74% of patients achieved at least a very good partial response at first line, compared with only 11% at fifth line. Deeper responses were associated with longer time to progression, although these were physician-judged. Toxicities and co-morbidities increased with later treatment lines, and were more likely to have led to discontinuation of treatment. These real-world data provide an insight into patient outcomes and treatment decisions being made in clinical practice.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/275849
Statistics
Document views: 56 File downloads: